Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic...
Transcript of Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic...
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
1/74
Ariyo Riyadi Rangga Putra0861050028
JOURNAL READING
Partial Dopamine D2/Serotonin 5-HT1A Receptor
Agonists as New Therapeutic Agents
Clinical Instructor
dr. Sabar Siregar, Sp.KJ
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
2/74
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists
as New Therapeutic Agents
Adeline Etievant, Ccile Btry, and Nasser Haddjeri
Laboratory of Neuropharmacology, Faculty of Pharmacy, University Lyon I,EAC CNRS 5006, 8 Avenue Rockefeller
69373 LYON Cedex 08 France
The Open Neuropsychopharmacology Journal, 2010, 3, 1-12
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
3/74
CONTENTS (1)
ABSTRACT
INTRODUCTION
- Regulation of brain DA and 5-HT transmission
DA system
DA partial agonist 5-HT system
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTSAND SCHIZOPHRENIA
- Therapeutic Agent for Schizophrenia
- Partial D2-Like Receptor Agonists in Schizophrenia
- 5-HT1A Receptor Agonists in Schizophrenia
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
4/74
Abstract
The therapeutic efficacy of current antipsychotic orantidepressant agents still present important drawbacks,such as delayed onset of action and a high percentage ofnon-responders.
The present review discusses the usefulness of partialdopamine D2/serotonin 5-HT1A receptors agonists in thetreatment of schizophrenia, major depression and bipolardisorder as well as in Parkinsons disease.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
5/74
Abstract
Partial agonists can behave as modulators since theirintrinsic activity or efficacy of a partial agonist depends onthe target receptor population and the local concentrationsof the natural neurotransmitter.
These drugs may restore adequate neurotransmission whileinducing less side effects.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
6/74
Abstract
In schizophrenia, partial DA D2/5-HT1A receptor agonists(like aripiprazole or bifeprunox), by stabilizing DA systemvia a preferential reduction of phasic DA release, reduceside effects i.e. extrapyramidal symptoms and improve
cognition by acting on 5-HT1A receptors.
Aripiprazole a promising agent for the treatment ofdepression since it potentiates the effect of SSRIs inresistant treatment depression.
Concerning bipolar disorders, aripiprazole may have only abenefit effect in the treatment of manic episodes.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
7/74
Abstract
Treatment of Parkinsons disease with partial DA D2/5-HT1Areceptor agonists remains still experimental.
Several studies suggest that these drugs decrease usuallyobserved side effects (dyskinesia, psychotic-like symptoms)in Parkinsons disease treatment.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
8/74
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
9/74
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
10/74
1. THE MESOLIMBIC DOPAMINERGIC PATHWAY
Located within the ventral tegmental area.
Efferent target in the ventral striatum including
nucleus accumbens (Nacc) and limbic structures(e.g amygdala and hippocampus).
Involved in emotional and motivationalprocessing.
In schizophrenia, the hyperactivation of thispathway seems to lead to positive symptoms likehallucinations.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
11/74
2. THE MESOCORTICAL DOPAMINERGIC PATHWAY
Efferent targets in prefrontal cortex.
This pathway is hypoactive in schizophrenia
which can be responsible for cognitive andnegative symptoms.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
12/74
3. THE NIGROSTRIATAL DOPAMINERGIC PATHWAY
Consists of the subst. nigra pars compacta (SNc-A9).
Efferent targets in the dorsal striatum.
Contains the majority of brain DA.
This pathway is involved in motor learning and control.
Degeneration of this pathway leads to Parkinsonsdisease.
Blockade of this pathway is associated with movementdisorders like EPS and dyskinesia.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
13/74
4. THE TUBERO-INFUNDIBULAR DA PATHWAY
Consists of DA neurons that project from theperiventricular and arcuate nuclei of the hypothalamus
to the intermediate lobe of the pituitary.
Secretion of prolactine under the control of DA.Blockade of DA receptors hyperprolactinemia.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
14/74
A partial agonist induces a reduced signaling responsecompared to the maximum achievable response by afull agonist.
The intrinsic activity or efficacy of a partial agonistdepends on the sensitivity and responsiveness of thereceptors.
A partial agonist can behave as an agonist orantagonist, depending on the target receptorpopulation and the local concentration of the naturalneurotransmitter.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA PARTIAL AGONISTS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
15/74
(Hypothetic of the mechanism of action of partial D2/5-HT1A agonists)
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
DA PARTIAL AGONIST
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
16/74
Located in the brainstem near or on the midline. There is nine 5-HT nuclei in the brainstem.
The superior group : the caudal linear nucleus,median raphe nuclei (MRN), dorsal raphe nuclei
(DRN), lateral nucleus. The inferior group : the nuclei raphe obscursus,
raphe pallidus, raphe magnus.
Efferent 5-HT projections to the forebrain originate
mainly from the superior group of raphe nuclei.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
5-HT SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
17/74
The DRN contains about 50-60% of 5-HT neurons inhuman CNS, whereas the MRN contains about 5%.
In the DRN, about 70% of the cells are 5-HT neurons.Non-5-HT cells found in the DRN : peptidergic
neurons (Substance P) and non-peptidegric neurons(DA and GABA).
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
5-HT SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
18/74
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
5-HT SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
19/74
5-HT1A receptors Located presynaptically on 5-HT neurons in the raphe
nuclei and post-synaptic neurons in the brain andspinal cord.
Exert negative feedback on firing activity.
Abundant in limbic structures, exert an inhibitoryfunction on neuronal activity.
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
INTRODUCTION Regulation of Brain DA and 5-HT Transmission
5-HT SYSTEM
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
20/74
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
21/74
Journal Reading from Medical Students of Christian University of IndonesiaClinical Instructordr. Sabar Siregar, Sp.KJ
Magelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
22/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
23/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
24/74
All antipsychotics reduce DA neurotransmission byblocking DA receptors.
Divided in two generations :
1. The first-generation typical antipsychotics
2. The second-generation atypical antipsychotics
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
THERAPEUTIC AGENTS FOR SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
25/74
The First-Generation Typical Antipsychotics Reduce DA neurotransmission by blocking DA
receptors, predominantly the D2 subtypes.
Reduce positive symptoms.
Causing important side effects : EPS.
EPS are directly related to D2 receptor blockade (up to80% od D2 receptor blockade) of the nigrostriatalpathway.
Other possible effect : hyperprolactinaemia.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
THERAPEUTIC AGENTS FOR SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
26/74
The Second-Generation Atypical Antipsychotics Have less side effects on the motor function.
Decrease both negative and positive symptoms.
Have important metabolic side effects : weight gain ordiabetes.
Have a higher affinity for 5-HT2A receptors than for D2receptors and blocks both receptor types.
Interact with a large range of other receptors,including cholinergic and serotoninergic receptors.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
THERAPEUTIC AGENTS FOR SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
27/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND SCHIZOPHRENIA
THERAPEUTIC AGENTS
FOR SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
28/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
29/74
Currently, aripiprazole is the only partial D2-like receptoragonist used for schizophrenia.
Other agents showing in vivo or in vitro partial D2-likereceptor activity represent putative antipsychotics, e.g.
bifeprunox, sarizotan, 3PPP, ACR16, OSU6162. Interestingly, the N-desmethylclozapine, the major
metabolites of clozapine, is also a partial D2-like agonist.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
PARTIAL D2-LIKE RECEPTOR AGONISTS IN SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
30/74
Haloperidol :At low dose increase firing activity. At high dose depolarization block. Chronic treatment decreasenumber of spontaneous active DA neurons in the VTA
reducing mesolimbic DA transmission. Aripiprazole :
Moderately decrease VTA DA neuronal firing. Chronictreatment does not affect neuronal firing. It also can
induce a stabilization of the DA neurotransmission.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
PARTIAL D2-LIKE RECEPTOR AGONISTS IN SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
31/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
PARTIAL D2-LIKE RECEPTOR AGONISTS IN SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
32/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
PARTIAL D2-LIKE RECEPTOR AGONISTS IN SCHIZOPHRENIA
/
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
33/74
Several compounds including clozapine, ziprasidone,and quetiapine have a partial agonistic effect on 5-HT1A receptors.
Recent drugs (bifeprunox, aripiprazole) are more
potent 5-HT1A receptor agonistic effect.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
34/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
35/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
36/74
5-HT1A receptor agonist 8-OH-DPAT increased theeffect of the D2-like antagonist raclopride in theconditioned avoidance response.
Clinical studies have shown a beneficial effect on
psychotic syndromes by simultaneous administrationof haloperidol (a typical antipsychotic) and buspirone(a partial 5-HT1A receptor agonist).
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN 5 HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
37/74
Cognitive impairments are associated with a decreaseof DA release in PFC.
Direct or indirect 5-HT1A receptor stimulation mayincrease DA release in prefrontal cortex.
Clinical studies have reported a beneficial effect of thesimultaneously administration of typical or atypicalantipsychotic and a 5-HT1A agonist (like tandospironeor buspirone) on cognitive deficits, including verbal
learning and memory.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN 5 HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
38/74
5-HT1A agonists induce anxiolytic and antidepressiveeffects in clinical studies, which makes thempotentially interesting for treatment of majordepression.
In this regard, compounds such as aripiprazole presentanxiolytic effects in preclinical tests of anxiety.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
PARTIAL DOPAMINE D /SEROTONIN 5 HT RECEPTOR AGONISTS AND SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
39/74
65% of D2 receptors occupancy is necessary for clinicalefficacy of treating psychotics, while it must notexceed 90% in order to avoid EPS.
Important to develop compounds able to increase this
narrow window. 5-HT1A agonist 8-OH-DPAT reversed the catalepsy
induced by D2 receptor antagonists or antipsychotics,by stimulation of the 5-HT1A autoreceptor in the median
raphe nuclei.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND SCHIZOPHRENIA
5-HT1A RECEPTOR AGONISTS IN SCHIZOPHRENIA
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
40/74
CONTENTS (2)
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVEDISORDERS
- Major Depression
- Therapeutic Agents for Major Depression
- D2-Like Receptor Agonists in Major Depression
- 5-HT1A Receptor Agonists in Major Depression- Bipolar Disorder
- Therapeutic Agents for Bipolar Disorder
- Partial D2-Like Receptor Agonists in Manic Episodes
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS ANDPARKINSONS DISEASE
- Therapeutic Agents for Parkinsons Disease- Partial D2-Like Receptor Agonists in PD
- 5-HT1A Receptor Agonists in PD
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D /SEROTONIN 5-HT A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
41/74
Prevalence rate 12% men and 20% women
Changes in mood
Several psychosiological
Decreased ability to concentrate
Reccurent thought of death
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
MAJOR DEPRESSION
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D /SEROTONIN 5-HT A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
42/74
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
MAJOR DEPRESSION
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D /SEROTONIN 5-HT RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
43/74
First generation antidepressant therapy(Tricyclic anti-depressants and IMAO)
Side effects : hypotension, retention urinary, sexual and
sleep impairment, toxicity lead to the search for moretolerable
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
THERAPEUTIC AGENTS FOR MAJOR DEPRESSION
PARTIAL DOPAMINE D /SEROTONIN 5-HT RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
44/74
SSRIs, selective noradrenaline reuptake inhibitors,noradrenaline and serotonin reuptake inhibitors or atypical
antidepressants
Have fewer and less severe side effects than these firstgeneration drugs due to their lack of affinity for amines and
acetylcholine receptors
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
THERAPEUTIC AGENTS FOR MAJOR DEPRESSION
PARTIAL DOPAMINE D /SEROTONIN 5-HT A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
45/74
Two major problems remain unresolved:
1. One-third of the patients does not respond to anytreatment and one-third shows only a partial responseto any first agent used at an adequate dose for asufficient time
2. There is an undesirable 3-8 weeks delay before theonset of therapeutic response to antidepressant drugs
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
THERAPEUTIC AGENTS FOR MAJOR DEPRESSION
PARTIAL DOPAMINE D /SEROTONIN 5-HT RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
46/74
Atypical antipsychotics can be effective as anti-manic orantidepressant agents, and therefore they are increasinglypopular as adjunctive agents in clinical therapy, for example:
1. Olanzapine + Fluoxetine
2. Risperidone + Citalopram
3. Aripiprazole
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
D2-LIKE RECEPTOR AGONISTS IN MAJOR DEPRESSION
PARTIAL DOPAMINE D /SEROTONIN 5-HT RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
47/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
5-HT1A RECEPTOR AGONISTS IN MAJOR DEPRESSION
5-HT neurons gradually recover their normal firing rateas a result of 5-HT1A autoreceptor desensitization.
This gradual recovery of 5-HT neuronal activity mayexplain the therapeutic delay of clinical action of these
drugs. Preclinical data suggest that postsynaptic 5-HT1A
receptors are particularly important for theantidepressant response.
PARTIAL DOPAMINE D /SEROTONIN 5-HT A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
48/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
5-HT1A RECEPTOR AGONISTS IN MAJOR DEPRESSION
First, the activation of these receptorsleads to behavioral changes in severalanimal models, such as the forced swimtest (FST), similar to those observedwith conventional antidepressants
Second, there is evidence thaneurogenesis, which is a crucialphenomenon in the antidepressantaction, can be mediated via 5-HTreceptor activation.
PARTIAL DOPAMINE D /SEROTONIN 5-HT A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
49/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
5-HT1A RECEPTOR AGONISTS IN MAJOR DEPRESSION
The azapirones (gepirone, buspirone, tandospirone andipsapirone) which act as partial 5-HT1A eceptor agonist have shownefficacy in the treatment of anxiety and major depression.
Buspirone is a commercially agent available but used as a singleagent appears to be non-effective.
Early clinical trials conducted with an immediate release (IR)formulation of gepirone, buspirone and ipsapirone showedantidepressant efficacy after eight weeks, but has thedisadvantages of poor tolerability (dizziness, nausea, insomnia,
headache and asthenia and a limited efficacy (short half-life andrapid absorption from the gastrointestinal tract).
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
50/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
5-HT1A RECEPTOR AGONISTS IN MAJOR DEPRESSION
Azapirones have been reformulated as an extended-release(ER) tablet which increases their half life, allowing more
gradual and sustained absorption from the gastrointestinaltract while lowering peak plasma gepirone concentration
Wilcox et al. showed that gepirone ER administration hadantidepressant efficacy 1 week until 6 weeks of treatment with a
daily dose of 70mg but not with 40mg
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
51/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5 HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
5-HT1A RECEPTOR AGONISTS IN MAJOR DEPRESSION
While these results from clinical trials support the efficacyand the tolerability of ER formulation of gepirone in majordepressive disorder, it should be noted that results are lessconclusive concerning other azapirones (buspirone and
ipsapirone). In addition, azapirones are rapidly metabolized into 1-(2-
pyrimidinyl)-piperazine (1-PP) which is an alpha-2adrenoreceptor antagonist, like mirtazapine an effective
antidepressant drug. However, the antidepressantlikeeffect of 1-PP is not well established
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
52/74
Bipolar disorder is a severe chronic illness associated withabnormal structure and function of the central nervoussystem with high rates of recurrence, disability, social
impairment1-6% of the population.
Specifically, the depressive episodes are morenumerous,last longer, and are less responsive to treatment
than the manic episodes
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
BIPOLAR DISORDER
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
53/74
The goals of pharmacological treatmentsfor bipolar disorder are:
First, to decrease this hyperexcitability andStabilize mood
Second, to prevent the recurrence ofdepressive and manic episodes
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
2 1A
THERAPEUTIC AGENTS FOR BIPOLAR DISORDER
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
54/74
Traditional mood-stabilizing:
Lithium
Anticonvulsive agents(valproate or lamotrigine)
20%-40% patient have sideeffects such as :
Tremors
Gastrointestinal disorders,
Tiredness
Somnolence, and cognitive
Impairment in memory andconcentration
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
2 1A
THERAPEUTIC AGENTS FOR BIPOLAR DISORDER
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
55/74
Short-term studies
(3-4 weeks) suggest thatatypical antipsychotics(olenzapine, risperidone,ziprasidone) have beneficial
effects on manic anddepressive episodes.
Longer-term managementof bipolar disorder
For example, aplacebocontrolled studyshowed maintenance ofthe efficacy of risperidonemonotherapy over 12weeks and aripiprazole
seems to have similaeffects.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
THERAPEUTIC AGENTS FOR BIPOLAR DISORDER
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
56/74
Studies have demonstrated that aripiprazole is effective andwell tolerated in the treatment of acute bipolar mania.
Aripiprazole had superior efficacy to haloperidol in responserates and tolerability in a 12-week acute mania trial in patients
with bipolar I disorder in acute manic or mixed episode
side effects aripripazole such as akathisia, insomnia,nausea,restless or dry mouth
2 5 1A
PARTIAL D2-LIKE RECEPTOR AGONISTS IN MANIC EPISODE
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
57/74
Aripiprazole monotherapy was superior to placebo inmaintaining efficacy in patients with a recent manic/mixed
episode who were stabilized and maintained on a regimen ofaripiprazole for 12 weeks, 26 weeks and 100 weeks Vieta et al.
demonstrated that adjunctive aripiprazole therapy to lithium orvalproate showed significant improvement in mania
symptoms from one week in bipolar patients with manic ormixed episodes who were partiall nonresponsive to
lithium/valproate monotherapy.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
2 1A
PARTIAL D2-LIKE RECEPTOR AGONISTS IN MANIC EPISODE
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1A RECEPTOR AGONISTS AND AFFECTIVE DISORDERS
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
58/74
The same result has been observed with other atypicalantipsychotics. The use of isperidone, olanzapine and
quetiapine as adjunctive agent enhanced the response toclassical treatment. While the beneficial effect of aripiprazole
was clear in the treatment of manic episodes, there is noevidence that aripiprazole monotherapy has superior efficacy
compared to placebo treatment at the end of the treatment inbipolar depression at the dose use.
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL D2-LIKE RECEPTOR AGONISTS IN MANIC EPISODE
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
59/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARKINSONS DISEASE
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
60/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
THERAPEUTIC AGENTS FOR PARKINSONS DISEASE
L-dihydroxyphenylalanine (L-DOPA) is presently the mosteffective treatment for PD.
Its use is associated with a high probability of motorcomplications, including abnormal involuntary movements
(dyskinesia) and motor fluctuations in 50% of PD patients.
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
61/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
PARTIAL D2-LIKE RECEPTOR FOR PD
Full DA receptor agonists can induce dyskinesia and psychotic-like
symptoms including hallucinations (probably due to theoverstimulation of extra-striatal DA receptors) or somnolence. Ithas been suggested that such side-effects could be counteractedby the use of partial D-like receptor agonists.
These compounds might stimulate D2 and D3 receptors when thedopaminergic tone is low, while counteracting excessivestimulation of the DA D2 and D3 receptor when the dopaminergictone is high.
It is also possible that partial agonists would modulate
dopaminergic transmission in a specific region, resulting in therestoration of dopaminergic transmission which is perturbed inPD patient.
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
62/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
5-HT1A RECEPTOR FOR PD
5-HT1A receptor agonists could reduce the incidence ofdyskinesia. The 5-HT1A receptor agonist tandospironereduced dyskinesia in L-DOPA treated PD patient
Preclinical and clinical studies suggest that sarizotan, a5-HT 1A receptor agonist that possesses weak D3 and D4receptor agonist activity, could ameliorate dyskineticsymptoms in association with L-DOPA.
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
63/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
5-HT1A RECEPTOR FOR PD
Studies with 5-HT1A agonists have suggested areduction in L-DOPA-induced dyskinesia but a worsePD disability.
Carta et al. have shown that dyskinesia induced by
chronic L-DOPA treatment in rats with 6-OHDA-induced lesions of the nigrostriatal DA pathway iscritically dependent on the integrity and function ofthe serotonergic system
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
64/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
5-HT1A RECEPTOR FOR PD
Synergistic effect of low doses of 5-HT1A and 5-HT agoniststo suppress dyskinesia, without affecting the anti-parkinsonian effect of L-DOPA in presence of spared DAterminals, suggests that early use of these drugs could
counteract the development of dyskinesia in PD patients. Wang et. al. have shown that unilateral lesion of the rat
nigrostriatal pathway induces an increase of neuronal firingof 5-HT neurons associated with desensitized 5-HT
autoreceptors.
PARTIAL DOPAMINE D2/SEROTONIN 5-HT1ARECEPTOR AGONISTS AND PARKINSONS DISEASE
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
65/74
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
5-HT1A RECEPTOR FOR PD
High frequency stimulation of the subthalamusnucleus, a well admit antiparkinsonian therapy, has
been shown to reduce 5-HT neuronal firing , furthersuggesting the involvement of 5-HT system in the
pathophysiology of PD.
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
66/74
CONCLUSION
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
Several studies are in accordance with the markedinterest of partial D2/5-HT1A agonists in reducing sideeffects i.e. extrapyramidal symptoms and cognitiveimpairments in schizophrenia, various researches arestill needed to emphasize their beneficial utility inmajor depression, bipolar disorders and Parkinsonsdisease.
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
67/74
CONCLUSION
Journal Reading from Medical Students of Christian University of Indonesia
Clinical Instructordr. Sabar Siregar, Sp.KJMagelang, 28 September 2012
Treatment with aripiprazole in major depression asmonotherapy or as adjuvant with a classical antidepressantsseems to improve the antidepressant response whereas, inbipolar disorder, only partial dopamin D2 1A receptorsagonists show advantages in the treatment of manic
episodes. Differently, if treatment of Parkinsons disease with partial D2
and 5-HT receptors agonists is still at the experimental phase,increasing studies report a decrease of side effects with thesedrugs. Hence, these relatively recent researches provide an
exciting future in the discovery of novel stabilizators agentsfor the management of the latter diseases.
JOURNAL READING
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
68/74
CRITICAL
APPRESIAL
Partial Dopamine D2/ Serotonin 5-HT1AReceptor Agonists as New Therapeutic Agents
THE STRUCTURE AND
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
69/74
THE STRUCTURE ANDCONTENT OF THE JOURNAL
The Title of Journal1. Not too long or too short : Yes (9 words)
2. Describe the whole of the journal : Yes
3. Interestingly enough : Yes4. Without abbreviations : Yes
The Author and InstitutionAppropriate with the guidelines : Yes
Ab t k
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
70/74
Abstrak1. The structure : Consist of 1 part
2. Informative : Yes
3. Less than 250 word : No (255 word)
Introduction
1. Consist of 2 paragraph or part : No(10 paragraph, 3 parts)
2. The first paragraph explain background of theresearch : Yes
3. The second paragraph explain hypothesis orobjective : Not pattern
4. Less than 1 page : Yes (3 pages)
The Literat re Re ie
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
71/74
The Literature Review1. The present state of play in relation to the topic : Yes
2. A range of up-to-date sources was reviewed : Yes
3. Key themes in the literature discussed and their significancewas shown : Yes
4. Gaps in the literature was identified : No
The Research Methods1. The context of the research is clear : Yes
2. The research methods are appropriate to the researchquestions : Not pattern
3. Methods are clearly justified : Not pattern4. The research sample was selected, and is it an appropriate
sample for the research questions : Not pattern
5. The methods are well executed : Not pattern
6. Ethical issues was addressed : Not pattern
The Data Analysis
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
72/74
The Data Analysis1. The main findings was described clearly : Yes
2. They was clearly related to the original research
questions : Yes3. They was presented in a format that is appropriate for
the findings : Not pattern
4. The interpretation of the data was consistent with theevidence : Yes
5. The findings is significant : Yes6. If quantitative: The data was analyzed using
appropriate statistical tools : Not pattern
7. If qualitative: Selection of data was presented : Notpattern
The Discussion
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
73/74
1. The data from the research related back to theliterature and to other findings : Yes
2. The research support or challenge existing thinking orpractice : Yes
3. The research suggest recommendations for practice, orareas for further research : Yes
4. The author reflective on her/his work or self-critical :
Not pattern
The Conclusion1. The threads of the argument was drawn together
clearly : Yes2. The research questions was answered and research
aims fulfilled : Yes
3. The research contribute to the field : Clinicians,Psychiatrist
-
7/30/2019 Journal Reading FK UKI (Partial Dopamine D2 Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents)
74/74
Thank You